Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators.
Van Mieghem NM, et al.
JAMA Cardiol. 2022 Oct 1;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695.
JAMA Cardiol. 2022.
PMID: 36001335
Free PMC article.
Clinical Trial.
Randomization was stratified by investigational site and need for revascularization determined by the local heart teams. Patients with severe aortic valve stenosis deemed to be at intermediate risk of 30-day surgical mortality were enrolled at 87 centers from June 19, 2012 …
Randomization was stratified by investigational site and need for revascularization determined by the local heart teams. Patients wit …